NASDAQ · Medical - Devices

NPCE (NPCE) Stock

$13.50 +4.73% NASDAQ: NPCE Healthcare

Valuation

MetricValue
Price$13.50
Market Cap$460.27M
P/E Ratio-23.92
P/B Ratio28.33
P/S Ratio5.26
EPS (TTM)$-0.66
52-Week High$19.60
52-Week Low$7.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-110.53%
ROA-19.81%
ROCE-84.21%
Gross Margin-16.00%
Operating Margin-16.00%
Net Margin-21.67%
Debt/Equity4.87
Current Ratio5.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$45.0M$46.0M$65.0M$80.0M$100.0M
Operating Profit$-24.0M$-41.0M$-27.0M$-22.0M$-16.0M
Net Profit$-36.0M$-47.0M$-33.0M$-27.0M$-21.0M
EPS$-2.17$-1.91$-1.27$-0.93$-0.66
Op Margin-52.5%-89.6%-41.5%-27.1%-16.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$134.0M$114.0M$108.0M$95.0M$106.0M
Total Liabilities$60.0M$79.0M$87.0M$87.0M$87.0M
Cash$19.0M$7.0M$18.0M$13.0M$22.0M
Borrowings$50.0M$70.0M$72.0M$73.0M$71.0M

Latest News

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now Zacks · Jul 15, 2026 NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™ Insider Monkey · Jun 27, 2026 Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade Zacks · Jun 15, 2026 NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? Zacks · Jun 11, 2026 Here's Why You Should Add NeuroPace Stock to Your Portfolio Now Zacks · Jun 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-25.0M$-37.0M$-20.0M$-18.0M$-11.0M
Investing Cash Flow$-86.0M$23.0M$23.0M$9.0M$-1.0M
Financing Cash Flow$-2.0M$0$0$1.0M$-50.0M
Net Cash Flow$-7.0M$-13.0M$11.0M$-5.0M$8.0M
Free Cash Flow$-25.0M$-37.0M$-20.0M$-18.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-1.88%
Quick Ratio4.35
Interest Coverage-2.29
Return 1Y54.53%
Return 3Y253.73%
Return 5Y-35.32%

Ownership

Insiders Held4.04%
Institutions Held96.28%
Institutions Float Held100.33%
Institutional HolderSharesReport Date
Polar Capital Holdings PLC3,298,1042026-03-31
Soleus Capital Management, L.P.2,932,2072026-03-31
Morgan Stanley2,566,8392026-03-31
First Light Asset Management, LLC2,459,9662026-03-31
Blackrock Inc.2,346,3332026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
BWAYBrainsWay Ltd. $16.56 +2.54% 72.48 $649.53M 0.00%
CERS $2.32 +2.20% -34.25 $467.54M 0.00%
CVRX $4.88 +2.95% -2.98 $129.50M 0.00%
DCTH $15.11 -2.33% 157.43 $521.62M 0.00%

About NPCE

NPCE is led by CEO Joel D. Becker, employs 184 people, headquartered in US, publicly traded since 2021.

NPCE stock trades at $13.50 with a market capitalization of $460.27M. The stock is valued at a price-to-earnings (P/E) ratio of -23.92, price-to-book of 28.33, price-to-sales of 5.26. Over the past 52 weeks the stock has ranged between $7.56 and $19.60, and currently trades 31.1% below its 52-week high.

On profitability, NPCE generates a return on equity (ROE) of -110.53%, return on capital employed of -84.21%, an operating margin of -16.00%, a net profit margin of -21.67%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides